Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

NCT ID: NCT05720559

Last Updated: 2023-02-09

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-01
• Study Completion Date: 2026-09-01

Brief Summary

In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer. A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods. The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.

Detailed Description

Patients diagnosed with colorectal cancer, clinical stage I to III, underwent radical surgery, and prehepatic CTC≥1 were enrolled. Patients were randomly divided into Conventional treatment group and Quintuple method treatment group. Patients in the Conventional treatment group received conventional treatment according to the NCCN Guidelines for Colorectal Cancer 2023 edition. For patients in the Quintuple method treatment group, Quintuple method intervention was adopted, that is, combined with SOX regimen chemotherapy, low-dose cetuximab targeted therapy and three-drug regimen of folic acid, vitamin A and metronidazole. Specific drug dosages were as follows: SOX regimen was administered every three weeks, d1 was given oxaliplatin intravenously, the dosage was 130mg/ m2 * patient's body surface area, d2-d15 was taken orally by Digio, 20mg three times a day each time. Cetuximab combined with chemotherapy was administered intravenously, once every three weeks, before oxaliplatin, and the dosage was 250mg/ m2 * patient's body surface area. Metronidazole 0.4g/ time, once a day; Vitamin A 25,000 units/time, once a day; Folic acid 0.4mg/ time, once a day. The last three drugs were continued until the end of all chemotherapy cycles. The above regimen lasted for 6 to 8 sessions, and enrolled patients were reviewed every 3 months for colorectal cancer-related tumor markers, including MRI and CT imaging. The primary endpoint was radiographically confirmed metachronous liver metastases, and the secondary endpoint was death, observed for 3 years.

Conditions

Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Conventional treatment group

Conventional treatment was performed according to the NCCN Guidelines for Colorectal Cancer 2023 Edition

Group Type: EXPERIMENTAL

Oxaliplatin

Intervention Type: DRUG

Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area

Capecitabine

Intervention Type: DRUG

Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.

Quintuple method treatment group

SOX regimen chemotherapy, low dose cetuximab targeted therapy, and folic acid, vitamin A, metronidazole three-drug regimen were combined. Specific drug dosages were as follows: SOX regimen was administered every three weeks, d1 was given oxaliplatin intravenously, the dosage was 130mg/ m2 \* patient's body surface area, d2-d15 was taken orally by S1, 20mg three times a day each time. Cetuximab combined with chemotherapy was administered intravenously, once every three weeks, before oxaliplatin, and the dosage was 250mg/ m2 \* patient's body surface area. Metronidazole 0.4g/ time, once a day; Vitamin A 25,000 units/time, once a day; Folic acid 0.4mg/ time, once a day. The last three drugs were continued until the end of all chemotherapy cycles. These regimens last for 6 to 8 sessions.

Group Type: EXPERIMENTAL

Oxaliplatin

Intervention Type: DRUG

Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area

S1

Intervention Type: DRUG

Orally on d2-d15 at 20 mg three times daily

Cetuximab

Intervention Type: DRUG

Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

Metronidazole

Intervention Type: DRUG

Metronidazole 0.4g/time, qd

Vitamin A

Intervention Type: DRUG

Vitamin A 25,000 units/time, qd

Folic acid

Intervention Type: DRUG

Folic acid 0.4 mg/time, qd

Interventions

Oxaliplatin

Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area

Intervention Type: DRUG

S1

Orally on d2-d15 at 20 mg three times daily

Intervention Type: DRUG

Cetuximab

Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

Intervention Type: DRUG

Metronidazole

Metronidazole 0.4g/time, qd

Intervention Type: DRUG

Vitamin A

Vitamin A 25,000 units/time, qd

Intervention Type: DRUG

Folic acid

Folic acid 0.4 mg/time, qd

Intervention Type: DRUG

Capecitabine

Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Ages 18-80 at the time of signing the informed consent;

2. Histologically or cytologically confirmed adenocarcinoma of the colon or rectum;

3. Radical surgery has been performed;

4. Imaging examination showed no liver metastasis;

5. Prehepatic CTC number ≥1;

6. The ECOG performance status is 0-1.

7. No combination of other life-threatening diseases;

8. Willingness and ability to follow scheduled visits, treatment plans, laboratory tests and other research procedures.

Exclusion Criteria

1. Patients with non-primary colorectal cancer;

2. Patients with liver metastasis or other organ metastasis;

3. Patients without prehepatic CTC or whose prehepatic CTC were negative;

4. People who are severely allergic to one or more of the drugs required in the test;

5. Patients with severe underlying diseases of respiratory, circulatory, urinary and hematopoietic systems.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Liaoning Cancer Hospital & Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zhang Zhongguo, Doctor

Role: STUDY_DIRECTOR

Liaoning Tumor Hospital & Institute Shenyang, Liaoning, China

Central Contacts

Zhang Zhongguo, Doctor

Role: CONTACT

Zhangzhongguoln@163.com

15840217908

Other Identifiers

20230201zzg

Identifier Type: -

Identifier Source: org_study_id